Author details

Full Name

Hien Dang

Affiliation

ORCID

Career Start Year

2008

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37224815	Tumor biology and immune infiltration define primary liver cancer subsets linked to overall survival after immunotherapy.	Cell Rep Med	2023
37415390	Implementation of deep learning in liver pathology optimizes diagnosis of benign lesions and adenocarcinoma metastasis.		2023
36797475	Stiff matrix induces exosome secretion to promote tumour growth.	Nat Cell Biol	2023
34778955	Noninvasive risk stratification of intraductal papillary mucinous neoplasia with malignant potential by serum apolipoprotein-A2-isoforms.	International Journal of Cancer	2022
35892825	Use of Autoreactive Antibodies in Blood of Patients with Pancreatic Intraductal Papillary Mucinous Neoplasms (IPMN) for Grade Distinction and Detection of Malignancy.	Cancers	2022
35865863	Reduced Rates of Post-Transplant Recurrent Hepatocellular Carcinoma in Non-Alcoholic Steatohepatitis: A Propensity Score Matched Analysis.	Transplant International	2022
36434060	Lung_PAYNet: a pyramidal attention based deep learning network for lung nodule segmentation.	Scientific Reports	2022
35063534	The role of RNA binding proteins in hepatocellular carcinoma.	Advanced Drug Delivery Reviews	2022
34564931	Evaluating Outcomes Related to Donor and Recipient Metabolic Environment: Macrosteatotic Allografts and Nonalcoholic Steatohepatitis.	Liver Transplantation	2022
35034369	Single-cell biology uncovers apoptotic cell death and its spatial organization as a potential modifier of tumor diversity in HCC.	Hepatology	2022
32502310	Intratumoral Î³Î´ T-Cell Infiltrates, Chemokine (C-C Motif) Ligand 4/Chemokine (C-C Motif) Ligand 5 Protein Expression and Survival in Patients With Hepatocellular Carcinoma.	Hepatology	2021
33884677	Simultaneous liver kidney allocation policy and the Safety Net: an early examination of utilization and outcomes in the United States.	Transplant International	2021
31188495	Depletion of TRRAP Induces p53-Independent Senescence in Liver Cancer by Down-Regulating Mitotic Genes.	Hepatology	2020
31941754	AGO2 Mediates mRNA Stability in Hepatocellular Carcinoma.	Molecular Cancer Research	2020
32209440	Understanding the Cause and Consequence of Tumor Heterogeneity.		2020
32487192	PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma.	J Exp Clin Cancer Res	2020
32933994	Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers.	Clin Cancer Res	2020
32850829	Hepatic Stellate Cells and Hepatocarcinogenesis.	Frontiers in Cell and Developmental Biology	2020
32942580	Hepatocellular Carcinoma-The Influence of Immunoanatomy and the Role of Immunotherapy.	International Journal of Molecular Sciences	2020
30833661	NELFE-Dependent MYC Signature Identifies a Unique Cancer Subtype in Hepatocellular Carcinoma.	Sci Rep	2019
31729408	Functional Genomic Complexity Defines Intratumor Heterogeneity and Tumor Aggressiveness in Liver Cancer.	Sci Rep	2019
30862714	Genome-Wide RNAi Screen Identifies PMPCB as a Therapeutic Vulnerability in EpCAM<sup>+</sup> Hepatocellular Carcinoma.	Cancer Res	2019
29315726	Single-cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma.	Hepatology	2018
30209397	Necroptosis microenvironment directs lineage commitment in liver cancer.	Nature	2018
30566427	Non-proteolytic ubiquitin modification of PPARÎ³ by Smurf1 protects the liver from steatosis.	PLoS Biol	2018
30410124	Author Correction: Necroptosis microenvironment directs lineage commitment in liver cancer.	Nature	2018
29303512	The significance of intertumor and intratumor heterogeneity in liver cancer.	Exp Mol Med	2018
28697339	Oncogenic Activation of the RNA Binding Protein NELFE and MYC Signaling in Hepatocellular Carcinoma.	Cancer Cell	2017
28648284	Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma.	Cancer Cell	2017
28603735	Cancer exosomes: wanted by many, explored by few, waiting for one.	Annals of Translational Medicine (discontinued)	2017
28743957	Ubiquitin-specific protease 21 stabilizes BRCA2 to control DNA repair and tumor growth.	Nat Commun	2017
26206664	LTÎ²R signalling preferentially accelerates oncogenic AKT-initiated liver tumours.	Gut	2016
26880118	Three-dimensional Organotypic Culture Models of Human Hepatocellular Carcinoma.	Sci Rep	2016
26000702	The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma.	PLoS ONE	2015
25886575	Induction of tumor initiation is dependent on CD44s in c-Metâº hepatocellular carcinoma.	BMC Cancer	2015
25833323	Hepatic stellate cell and monocyte interaction contributes to poor prognosis in hepatocellular carcinoma.	Hepatology	2015
24955791	Identification of drivers from cancer genome diversity in hepatocellular carcinoma.	Int J Mol Sci	2014
24631602	The origin of cancer stem cells.	J Hepatol	2014
23552699	miR-200b restoration and DNA methyltransferase inhibitor block lung metastasis of mesenchymal-phenotype hepatocellular carcinoma.	Oncogenesis	2012
21618573	c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma.	Hepatology	2011
21929801	Snail1 induces epithelial-to-mesenchymal transition and tumor initiating stem cell characteristics.	BMC Cancer	2011
22006186	Isolation of CD133+ liver stem cells for clonal expansion.	Journal of Visualized Experiments	2011
20564331	Epithelial-to-mesenchymal transition of murine liver tumor cells promotes invasion.	Hepatology	2010
20837017	Expansion of hepatic tumor progenitor cells in Pten-null mice requires liver injury and is reversed by loss of AKT2.	Gastroenterology	2010
21092202	Clinical application for the preservation of phospho-proteins through in-situ tissue stabilization.	Proteome Science	2010
18487508	SALL4 is a key regulator of survival and apoptosis in human leukemic cells.	Blood	2008